PURPOSE: We studied bone marrow angiogenesis in different stages of multiple myeloma according to the Durie and Salmon classification and its correlations with other disease characteristics. METHODS: Sixty-five immunohistochemical CD34-stained, paraffin-embedded bone marrow biopsies of multiple myeloma patients and 12 controls were studied. The mean number of microvessels per area in each sample was determined as the microvessel density (MVD). In addition, plasma cell infiltration of the bone marrow, serum beta2-microglobulin, immunoglobulin levels, C-reactive protein, and serum calcium concentration were measured in 22 patients with stage I multiple myeloma and in 43 patients in stage II-III. RESULTS: In myeloma patients, the bone marrow MVD was significantly higher than in controls (P<0.001). In 43 patients with stage II-III multiple myeloma, MVD was significantly higher than in 22 patients with stage I (median MVD 46 and 21 vessels/mm(2), respectively, P=0.005). Additionally, in stage II-III the bone marrow MVD correlated positively with the bone marrow plasma cell infiltration (r=0.55, P<0.001) and the serum beta2-microglobulin level (r=0.53, P<0.001), while in stage I patients no correlation could be found. CONCLUSIONS: Angiogenesis is significantly increased in stage II-III myeloma in comparison to stage I. In stages II-III, bone marrow angiogenesis is correlated with plasma cell infiltration and serum beta2-microglobulin levels.
PURPOSE: We studied bone marrow angiogenesis in different stages of multiple myeloma according to the Durie and Salmon classification and its correlations with other disease characteristics. METHODS: Sixty-five immunohistochemical CD34-stained, paraffin-embedded bone marrow biopsies of multiple myelomapatients and 12 controls were studied. The mean number of microvessels per area in each sample was determined as the microvessel density (MVD). In addition, plasma cell infiltration of the bone marrow, serum beta2-microglobulin, immunoglobulin levels, C-reactive protein, and serum calcium concentration were measured in 22 patients with stage I multiple myeloma and in 43 patients in stage II-III. RESULTS: In myelomapatients, the bone marrow MVD was significantly higher than in controls (P<0.001). In 43 patients with stage II-III multiple myeloma, MVD was significantly higher than in 22 patients with stage I (median MVD 46 and 21 vessels/mm(2), respectively, P=0.005). Additionally, in stage II-III the bone marrow MVD correlated positively with the bone marrow plasma cell infiltration (r=0.55, P<0.001) and the serum beta2-microglobulin level (r=0.53, P<0.001), while in stage I patients no correlation could be found. CONCLUSIONS: Angiogenesis is significantly increased in stage II-III myeloma in comparison to stage I. In stages II-III, bone marrow angiogenesis is correlated with plasma cell infiltration and serum beta2-microglobulin levels.
Authors: R Chaudhary; M Bromley; N W Clarke; C D Betts; R J Barnard; W D Ryder; S Kumar Journal: Anticancer Res Date: 1999 Jul-Aug Impact factor: 2.480
Authors: A Aguayo; H Kantarjian; T Manshouri; C Gidel; E Estey; D Thomas; C Koller; Z Estrov; S O'Brien; M Keating; E Freireich; M Albitar Journal: Blood Date: 2000-09-15 Impact factor: 22.113
Authors: B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast Journal: Blood Date: 2000-04-15 Impact factor: 22.113
Authors: Ramón García-Sanz; Maria Isabel González-Fraile; Magdalena Sierra; Carlos López; Marcos González; Jesús Fernando San Miguel Journal: Hematol J Date: 2002
Authors: Dan Jia; Nathan A Koonce; Roopa Halakatti; Xin Li; Shmuel Yaccoby; Frances L Swain; Larry J Suva; Leah Hennings; Marc S Berridge; Scott M Apana; Kevin Mayo; Peter M Corry; Robert J Griffin Journal: Radiat Res Date: 2010-06 Impact factor: 2.841
Authors: Ivana Zavrski; Cord Naujokat; Kathrin Niemöller; Christian Jakob; Ulrike Heider; Corinna Langelotz; Claudia Fleissner; Jan Eucker; Kurt Possinger; Orhan Sezer Journal: J Cancer Res Clin Oncol Date: 2003-07-08 Impact factor: 4.553
Authors: Ulrike Heider; Ivana Zavrski; Christian Jakob; Katharina Bängeroth; Claudia Fleissner; Corinna Langelotz; Kurt Possinger; Lorenz C Hofbauer; Volker Viereck; Orhan Sezer Journal: J Cancer Res Clin Oncol Date: 2004-06-15 Impact factor: 4.553
Authors: Nuri Lee; Hyewon Lee; Soo Young Moon; Ji Yeon Sohn; Sang Mee Hwang; Ok Jin Yoon; Hye Sun Youn; Hyeon Seok Eom; Sun Young Kong Journal: Ann Lab Med Date: 2015-11 Impact factor: 3.464